Atai life sciences to present at the cowen psychedelics & novel mechanisms in neuropsychiatry summit

Berlin, germany, july 07, 2021 (globe newswire) -- atai life sciences n.v. (nasdaq: atai) (“atai”), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced that it will present and participate in one-on-one investor meetings at the cowen psychedelics & novel mechanisms in neuropsychiatry summit on july 13, 2021.
ATAI Ratings Summary
ATAI Quant Ranking